Furmonertinib qd po
PreclinicalSmall molecule
Furmonertinib qd po is one of 15 small molecule programs targeting Leptomeningeal Metastasis. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Leptomeningeal Metastasis
#DrugCompanyPhaseTrials
1Lenvima
EisaiApproved
Cytosar
TevaApproved
Trexall
Jazz PharmaceuticalsApproved
Alimta
SShawn Eagle
Phase 2
Tepadina
Jazz PharmaceuticalsPhase 2
Intrathecal Chemotherapy
PPrincess Maxima Center for Pediatric Oncology
Phase 3
Furmonertinib
AAllist Pharmaceuticals, Inc.
Phase 2
AK112
SSummit Therapeutics
Phase 2
Tagrisso
AstraZenecaPreclinical
Rybrevant
Johnson & JohnsonPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Leptomeningeal Metastasis1 trial
Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
Not yet recruiting·GGuangzhou University of Traditional Chinese Medicine·N/A·NCT07348965·42 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Furmonertinib qd po. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details